Andrew Ferretti
Director, Technology & Platform Discovery TScan Therapeutics
Andrew Ferretti is Director of Technology & Platform Discovery at TScan Therapeutics, a clinical-stage biotechnology company developing T cell therapies for cancer and autoimmune disease. TScan’s proprietary TargetScan platform drives comprehensive target discovery, enabling the identification of disease-associated T cell targets across oncology and autoimmunity.
Seminars
Thursday 5th March 2026
TScan’s Antigen Discovery Platform Enables Tolerizing Therapies Through Identification of CD8⁺ and CD4⁺ T cell Targets
1:00 pm
- Introduction to TargetScan, a cell-based, unbiased platform that pairs naturally presented antigens with their cognate TCRs
- Demonstrating TargetScan’s ability to identify both CD8⁺ and CD4⁺ T cell targets in example indications such as ankylosing spondylitis, birdshot uveitis, scleroderma, and ulcerative colitis
- Exploring novel biologically validated targets that enable antigen-specific tolerizing therapies in indications such as ankylosing spondylitis
